V ascular endothelial growth factor (VEGF) is a hypoxiainducible secreted protein that interacts with receptor tyrosine kinases on endothelial cells to promote angiogenesis. Recent evidence indicates that VEGF can also act directly on neurons to produce neurotrophic and neuroprotective effects. For example, VEGF stimulates axonal outgrowth and improves the survival of cultured superior cervical and dorsal root ganglion neurons (1, 2) , enhances the survival of mesencephalic neurons in organotypic explant cultures (3), protects HN33 (mouse hippocampal neuron ϫ neuroblastoma) cells from death induced by serum withdrawal (4) , reduces hypoxic death of HN33 cells and cultured cerebral cortical neurons (5) , and protects cultured hippocampal neurons from glutamate toxicity (6) . Conversely, inhibition of VEGF signaling leads to apoptosis in cortical neuron cultures (7) , and deletion of the hypoxiaresponse element from the VEGF promoter causes motorneuron degeneration in mice (8) , perhaps because of loss of a direct neurotrophic effect of VEGF. Neurogenesis, the process through which precursor cells differentiate toward a mature neuronal phenotype, persists in discrete regions of the adult brain, including the rostral subventricular zone (SVZ) (9, 10) and the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) (11) . Comparatively little is known regarding the possible role of VEGF in adult neurogenesis, although other growth factors, including epidermal growth factor (EGF) (12) , fibroblast growth factor-2 (FGF-2) (13), brain-derived neurotrophic factor (BDNF) (14) , and erythropoietin (15) , have been implicated. In addition, the VEGF receptor Flk-1 is expressed in neural progenitor cells of the mouse retina (16) , and its activation stimulates their differentiation into amacrine neurons and photoreceptor cells (17) . Finally, neurogenesis in the adult SGZ appears to occur in intimate association with angiogenesis, suggesting that common factors, such as VEGF, might be involved in both processes (18) .
To investigate the possibility that VEGF is a neurogenic as well as an angiogenic factor, we examined its effects in in vitro and in vivo models of neurogenesis, by using the cellproliferation marker 5-bromodeoxyuridine (BrdUrd). The in vitro model employs primary cultures of embryonic rat cortical neurons, and has been used to identify growth factors involved in hypoxia-induced neurogenesis, including heparin-binding EGF (19) . The in vivo model involves intracerebroventricular (i.c.v.) administration of growth factors in the adult rat, and has been used to study the induction of neurogenesis in the brain in vivo by factors such as EGF, FGF-2, and BDNF (20) (21) (22) .
Materials and Methods
Materials. VEGF, BrdUrd 5Ј-monophosphate sodium salt, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were from Sigma, and SU1498 was from CalbiochemNovabiochem.
Cell Culture. Animal studies were approved by the local Institutional Animal Care and Use Committee. Cortical cultures enriched in cells of neuronal lineage were prepared from 16-day Charles River CD1 mouse embryos as described (5) , except that Neurobasal medium containing 1ϫ B27 supplement, 2 mM glutamate, and 1% penicillin and streptomycin was used (23) . After 4 days, one-half of the medium was replaced with Neurobasal medium containing 2% B27, and experiments were conducted at 5 days in vitro.
BrdUrd Labeling in Vitro. BrdUrd 5Ј-monophosphate (50 g͞ml) was added to cultures for 24 h. For immunocytochemistry, cultures were fixed in 4% paraformaldehyde in PBS (pH 7.5) for 40 min, washed with PBS, incubated for 2 h with blocking buffer (2% horse serum͞1% BSA͞0.1% Triton X-100 in PBS, pH 7.5), incubated overnight at 4°C with mouse monoclonal anti-BrdUrd (Roche Applied Science; 2 g͞ml), and then incubated for 1 h at room temperature with rhodamine-conjugated goat antimouse IgG (Jackson ImmunoResearch; 1:200). BrdUrdimmunoreactive cells were counted in five 200ϫ microscope fields per well (at the12-, 3-, 6-, and 9-o'clock positions and in the center). In some experiments, BrdUrd incorporation was measured with a commercially available enzyme-linked immunosorbent assay kit (Roche Applied Science).
Cell Viability. Cell viability was assayed by MTT absorbance and by counting cells on photomicrographs of 4Ј,6-diamidino-2-This paper was submitted directly (Track II) to the PNAS office.
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phenylindole (DAPI)-stained cultures (Vector Laboratories, Burlingame, CA). For MTT assays, cultures were incubated with 5 mg͞ml MTT at 37°C for 2 h, and absorbance at 570 nm was measured in solubilized cells by using a Cytofluor series 4000 multiwell plate reader (Applied Biosystems, Foster City, CA). For cell counting, the number of intact DAPI-stained nuclei in five 200ϫ microscope fields per well (at the 3-, 6-, 9-, and 12-o'clock positions and in the center) was recorded. In both cases, results were expressed as a percentage of values obtained in control cultures not treated with VEGF.
Immunocytochemistry. Cell cultures (24) and brain sections (25) were processed for immunocytochemistry and double-label immunocytochemistry as described. For double-label immunocytochemistry, sections were fixed with 4% paraformaldehyde in PBS for 1 h at room temperature, washed twice with PBS, and incubated in 2 M HCl at 37°C for 1 h. Sections were incubated with blocking solution, with primary antibodies at 4°C overnight, and with secondary antibodies in blocking solution at room temperature for 2 h. Primary antibodies were as follows: mouse monoclonal anti-BrdUrd (2 g͞ml; Roche Applied Science); sheep polyclonal anti-BrdUrd (25 g͞ml; Biodesign International, Saco, ME); rat monoclonal anti-embryonic nerve cell adhesion molecule (ENCAM, 1:100) and mouse monoclonal anti-nestin (1:400) (BD Biosciences Pharmingen, San Diego); affinity-purified rabbit polyclonal anti-VEGFR1͞Flt-1 (1:500), mouse monoclonal anti-VEGFR-2Flk-1 (1:500) and affinitypurified goat polyclonal anti-doublecortin (Dcx, 1:100) (Santa Cruz Biotechnology); rabbit polyclonal anti-cleaved (17-20 kDa) caspase-3 (1:500; New England Biolabs); mouse monoclonal anti-neuronal nuclear antigen (NeuN) (1:200; Chemicon); and mouse monoclonal anti-glial fibrillary acidic protein (GFAP, 1:500) and rabbit polyclonal anti-von Willebrand factor (vWF; 1:500; Sigma). Biotinylated goat anti-mouse IgG and FITC-(Vector Laboratories) or rhodamine-conjugated secondary antibodies (Jackson ImmunoResearch) were used (all 1:200). DAPI was used to counterstain nuclei in some cases and fluorescence signals were detected with a Nikon E300 or E800 microscope at excitation͞emission wavelengths of 535͞565 nm (rhodamine, red), 470͞505 (FITC, green), and 360͞400 (DAPI, blue). Biotin signals were detected with 3,3Ј-diaminobenzidine (DAB; brown) and Vector VIP (purple). Results were recorded with a Magnifire digital camera (ChipCoolers, Warwick, RI). Controls included omitting or preabsorbing primary antibody and omitting secondary antibody. For confocal microscopy, a Nikon PCM-2000 laser-scanning confocal microscope and Simple PCI imaging software (Compix, Cranberry Township, PA) were used.
VEGF Administration and BrdUrd Labeling in Vivo. VEGF was administered i.c.v. in artificial cerebrospinal fluid (aCSF) consisting of 128 mM NaCl, 2.5 mM KCl, 0.95 mM CaCl 2 , and 1.99 mM MgCl 2 . VEGF (10 g͞ml) or aCSF was infused at 1 l͞h for 3 days with an osmotic minipump (Alzet 1003D; Alza Scientific Products, Mountain View, CA), and BrdUrd 5Ј-monophosphate (50 mg͞kg in saline i.p.) or saline was given twice daily for the same number of days. Brains (four per condition) were removed after perfusion with saline and 4% paraformaldehyde in PBS. Fifty-micrometer coronal sections were cut with a cryostat and stored at Ϫ80°C. Sections were treated with 50% formamide͞ 280 mM NaCl͞30 mM sodium citrate at 65°C for 2 h, incubated in 2 M HCl at 37°C for 30 min, and rinsed in 0.1 M boric acid (pH 8.5) at room temperature for 10 min. Sections were then incubated in 1% H 2 O 2 in PBS for 15 min, in blocking solution (2% goat serum͞0.3% Triton X-100͞0.1% BSA in PBS) for 2 h at room temperature, and with 2 g͞ml mouse monoclonal anti-BrdUrd antibody (Roche Applied Science) at 4°C overnight. Sections were washed with PBS, incubated with biotinylated goat-anti-mouse secondary antibody (Vector Laboratories, 1:200) for 2 h at 25°C, washed, and placed in avidinperoxidase conjugate (Vector Laboratories) solution for 1 h. The horseradish peroxidase reaction was detected with 0.05% diaminobenzidine and 0.03% H 2 O 2 . Processing was stopped with H 2 O and sections were dehydrated through graded alcohols, cleared in xylene, and coverslipped in permanent mounting medium (Vector Laboratories). Sections were examined with a Nikon E300 epifluorescence microscope.
Statistics. All experiments were repeated at least three times. The statistical significance of differences between means was evaluated by Student's t test for single, and by ANOVA followed by post hoc t tests for multiple, comparisons, with P Ͻ 0.05 considered significant.
Results

VEGF Stimulates Neurogenesis in Cortical Cultures in Vitro.
Cortical cultures primarily contained cells of neuronal lineage, as demonstrated by the expression of phenotypic markers in the following percentages of cells: calbindin, Ϸ15%; Hu, Ϸ80%; ENCAM, Ϸ80%; ␤III tubulin, Ϸ75%; nestin, Ϸ25%; Neuro D, Ϸ5%; and GFAP, Ϸ2% (19) . When these cultures were treated with VEGF for 24 h in vitro, they showed increased incorporation of BrdUrd into cells that expressed the immature neuronal marker ENCAM or the neuroepithelial precursor cell marker nestin (Fig. 1) . This effect was concentration-dependent and was associated with an increase in cell number (DAPI-stained nuclei). The concentration-response relationships for stimulation of BrdUrd labeling and for elevation of cell number by VEGF were similar, with maximal effects at 10 ng͞ml.
VEGF Stimulates Neurogenesis in Vitro Through VEGFR2͞Flk-1 Receptors.
To identify the receptor mechanism involved in the stimulation of BrdUrd labeling by VEGF, cultures were immunostained with antibodies against VEGFR1͞Flt-1 and VEGFR2͞ Flk-1. VEGFR2͞Flk-1 was expressed in almost all cells, whereas VEGFR1͞Flt-1 was barely detectable by immunocytochemistry (Fig. 2) , despite the fact that the antibody used is capable of staining neuronal VEGFR1͞Flt-1 receptors (5). In addition, the VEGFR2͞Flk-1 receptor tyrosine kinase inhibitor SU1498 blocked the ability of 10 ng͞ml VEGF to increase BrdUrd labeling, at concentrations (1-100 M) associated with previ- 20ϫ). Note that BrdUrd incorporation is not confined to neuroproliferative zones, but extends, for example, into the dentate hilus in (A) consistent with the labeling of both neuronal and non-neuronal (e.g., astroglial) cells (see Fig. 6 ). Data are representative fields from at least three experiments per panel. ously reported effects of SU1498, such as inhibition of VEGFinduced up-regulation of endothelial nitric oxide synthase (26) .
VEGF Stimulates Neurogenesis in Rat Brain in Vivo.
To determine whether VEGF also stimulates BrdUrd incorporation in the rat brain in vivo, VEGF (10 g͞ml) was continuously infused i.c.v. at 1 l͞h for 3 days by means of a minipump and BrdUrd 5Ј-monophosphate (50 mg͞kg i.p.) was given twice daily over the same period, and brains were examined 1 wk later. Sections through the two principal neuroproliferative regions of the adult brain showed that VEGF increased BrdUrd labeling in both SGZ and SVZ (Fig. 3) . As was also true of cells that incorporated BrdUrd in response to VEGF in our cell cultures, these regions expressed abundant VEGFR2͞Flk-1 but not VEGFR1͞Flt-1 receptors (Fig. 4) . Moreover, VEGFR2͞Flk-1 receptor expression colocalized with the immature neuronal marker protein Dcx (27, 28) .
VEGF Does Not Modify Caspase-3-Dependent Cell Death in SGZ of Rat
Brain. A significant proportion of newly generated cells in neuroproliferative zones of the rodent brain normally die soon after mitosis (29) , which appears to be because of caspase-3-dependent programmed cell death (30) . Therefore, VEGF could increase the number of BrdUrd-labeled cells by inhibiting cell death rather than stimulating cell birth. To distinguish between these possibilities, SGZ and SVZ from VEGF-and aCSFvehicle-treated mouse brains were stained with an antibody against activated caspase-3. The number of activated caspase-3-immunopositive cells in SGZ and SVZ was modestly increased in VEGF-treated compared with control rats (Fig. 5) , indicating that the increase in BrdUrd labeling after VEGF treatment is not because of a reduction in caspase-3-mediated programmed cell death. (That VEGF might reduce caspase-3-independent cell death remains a possibility.) The increase in the number of cells expressing activated caspase-3 (Fig. 5) is considerably less than the corresponding increase in cells that show BrdUrd labeling (Fig. 3) , consistent with a net increase in cell numbers after VEGF treatment.
VEGF Stimulates Incorporation of BrdUrd into Both Neuronal and
Non-Neuronal Cells of Rat Brain in Vivo. To ascertain whether VEGF induced the incorporation of BrdUrd into neurons in vivo, as demonstrated above in vitro, brain sections from VEGF-and aCSF-vehicle-treated rats were processed for double-label immunohistochemistry with antibodies against BrdUrd and against cell-type-specific markers. Cells that incorporated BrdUrd by 7 days after the onset of VEGF treatment included Dcx-expressing immature neurons of SGZ and SVZ, as well as NeuN-immunopositive mature neurons, GFAP-staining astrocytes, and endothelial cells that expressed vWF (Fig. 6) . Therefore, VEGF stimulated BrdUrd incorporation into brain cells of both neuronal and nonneuronal lineages in vivo.
Discussion
The major finding of this study is that VEGF, identified originally as an angiogenic and vascular permeability factor, and more recently as a neurotrophic and neuroprotective factor, can also stimulate neurogenesis, identified by increased BrdUrd labeling of neuronal precursor cells in vitro and in vivo. The in vitro effect appears to be mediated through VEGFR2͞Flk-1 receptors because these were the VEGF receptors expressed in our cultures, and because the VEGFR2͞Flk-1 receptor tyrosine kinase inhibitor SU1598 blocked VEGF-stimulated BrdUrd labeling. The in vivo effect was observed in both of the major neuroproliferative zones of the adult rat brain-SGZ and SVZ, where VEGFR2͞Flk-1 receptors also predominated-and extended to astroglial and endothelial as well as neuronal cell lineages.
VEGF exerts multiple effects on endothelial cells, acting as a mitogen (31, 32) , promoting cell survival (33, 34) , and protecting cells from injury (35, 36) . Taken together with prior evidence for survival-promoting and protective effects of VEGF on neurons, our findings suggest that VEGF regulates a similarly broad range of functions in neurons. This is not necessarily surprising, since neurons express some of the same VEGF receptors and VEGF receptor-coupled signal transduction pathways that are found in the endothelium (1-8) .
Palmer et al. (18) reported that in the adult rat SGZ, neurogenesis occurs in close proximity to blood vessels, where VEGF expression is high and angiogenesis is ongoing. Based on this and other evidence, they argued that neurogenesis and angiogenesis might be mechanistically linked, citing VEGF as a factor that might provide such a linkage. The results presented here are consistent with that hypothesis.
The ability of VEGF to stimulate the proliferation of neuronal precursors may be of interest in the context of lesion-induced neurogenesis, which occurs after excitotoxicity (38) , seizures (39) , oxidative stress (40) , and global (41) and focal (25) ischemia. Particularly in cerebral ischemia, where VEGF expression is known to be increased (42) and to promote angiogenesis (43) , coordinate induction of angiogenesis and neurogenesis by a common factor could have adaptive value, by efficiently promoting brain recovery and repair. The induction of neurogenesis and angiogenesis in tandem could also be important in development, and a role for VEGF in this process has been proposed (44) . 
